Cryptococcus remains an important opportunistic infection in HIV patients despite considerable declines in prevalence during the highly active antiretroviral therapy era. This is particularly apparent in sub-Saharan Africa, where Cryptococcus continues to cause significant mortality and morbidity. This review discusses the microbiology, epidemiology, pathogenesis and clinical presentation of cryptococcal infections in HIV patients. Additionally, a detailed approach to the management of cryptococcosis is provided.
HajjehRA, BrandtME, PinnerRW. Emergence of cryptococcal disease: epidemiologic perspectives 100 years after its discovery. Epidemiol Rev1995;17:303–20
2.
BekondiC, BernedeC, PassoneN, Primary and opportunistic pathogens associated with meningitis in adults in Bangui, Central African Republic, in relation to human immunodeficiency virus serostatus. Int J Infect Dis2006;10:387–95
LotholaryO, PoizatG, ZellerV, Long-term outcome of AIDS-associated cryptococcosis in the era of combination antiretroviral therapy. AIDS2006;20:2183–91
5.
ImwidthayaP, PoungvarinN. Cryptococcosis in AIDS. Postgrad Med J2000;76:85–8
6.
BicanicT, MeintjesG, WoodR, Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naïve or -experienced patients treated with amphotericin B or fluconazole. Clin Infect Dis2007;45:76–80
7.
MwabaP, MwansaJ, ChintuC, Clinical presentation, natural history, and cumulative death rates of 230 adults with primary cryptococcal meningitis in Zambian AIDS patients treated under local conditions. Postgrad Med J2001;77:769–73
8.
PerfectJR, DismukesWE, DromerF, Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Disease Society of America. Clin Infect Dis2010;50:291–322
9.
BoversM, HagenF, BoekhoutT. Diversity of the Cryptococcus neoformans–Cryptococcus gattii species complex. Rev Iberoam Micol2008;25:S4–S12
10.
EmmonsCW. Saprophytic sources of Cryptococcus neoformans associated with the pigeon (Columba livia). Am J Hyg1955;62:227–32
11.
AjelloL. Occurrence of Cryptococcus neoformans in soils. Am J Hyg1958;67:72–7
12.
EllisDH, PfeifferTJ. Natural habitat of Cryptococcus neoformans var. gattii. J Clin Microbiol1990;28:1642–4
13.
LindbergJ, HagenF, LaursenA, StenderupJ, BoekhoutT. Cryptococcus gattii risk for tourists visiting Vancouver Island, Canada. Emerg Infect Dis2007;13:178–9
14.
FyfeM, MacDougallL, RomneyM, Cryptococcus gattii infections on Vancouver Island, British Columbia, Canada: emergence of a tropical fungus in a temperate environment. Canada Commun Dis Rep2008;34:1–12
15.
SinghN, DromerF, PerfectJ, LortholaryO. Cryptococcosis in solid organ transplant recipients: current state of the science. Clin Infect Dis2008;47:1321–7
16.
HageCA, WoodKL, Winer-MuramHT, WilsonSJ, SarosiG, KnoxKS. Pulmonary cryptococcosis after initiation of anti-tumor necrosis factor-alpha therapy. Chest2003;124:2395–7
17.
Centers for Disease Control and Prevention. 1993 Revised system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR1992;41:1–19
18.
MirzaS, PhelanM, RimlandD, The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large population areas, 1992–2000. Clin Infect Dis2003;36:789–94
19.
ParkBJ, WannemuehlerKA, MarstonBJ, GovenderN, PappasPG, ChillerTM. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS2009;23:525–30
20.
EllisDH, PfeifferTJ. The ecology of Cryptococcus neoformans. Eur J Epidemiol1992;8:321–5
21.
PattersonTF, AndrioleVT. Current concepts in cryptococcosis. Eur J Clin Microbiol Infect Dis1989;8:457–65
22.
BhattacharjeeAK, Kwon-ChungKJ, GlaudemansCPJ. The major capsular polysaccharide of Cryptococcus neoformans serotype B. Carbohydr Res1992;233:271–2
23.
PerfectJR, WongB, ChangYC, Kwon-ChungKJ, WilliamsonPR. Cryptococcus neoformans: virulence and host defences. Med Mycol1998;36Suppl. 1:79–86
24.
JarvisJ, DromerF, HarrisonT, LortholaryO. Managing Cryptococcus in the immunocompromised host. Curr Opin Infect Dis2008;21:596–603
25.
LortholaryO, PoizatG, ZellerV, Long-term outcome of AIDS-associated cryptococcosis in the era of combination antiretroviral therapy. AIDS2006;20:2183–91
26.
EngRHK, BishburgE, SmithSM, KapilaR. Cryptococcal infections in patients with acquired immune deficiency syndrome. Am J Med1986;81:19–23
27.
DismukesWE. Cryptococcal meningitis in patients with AIDS. J Infect Dis1988;157:624–8
28.
WilburL, HeyborneR. Transient loss of consciousness caused by cryptococcal meningitis in an immunocompetent patient: a case report. Cases J2009;2:60
29.
YuanjieZ, JianghanC, JulinG, HaiW. Cryptococcus meningitis in an immunocompetent 8 year old girl. Mycoses2008:1–2
BennettJE, BaileyJW. Control for rheumatoid factor in the latex test for cryptococcosis. Am J Clin Pathol1971;56:360–5
32.
PappasP, PerfectJR, CloudGA, Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin Infect Dis2001;33:690–9
33.
KhannaN, ChandramukiA, DesaiA, RaviV. Cryptococcal infections of the central nervous system: an analysis of predisposing factors, laboratory findings and outcomes in patients from South India with special reference to HIV infection. J Med Microb1996;45:376–9
34.
DiamondRD, BennettJE. Prognostic factors in cryptococcal meningitis: a study of 111 cases. Ann Intern Med1974;80:176–81
35.
KaplanJE, BensonC, HolmesKH, BrooksJT, PauA, MasurH. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Centers for Disease Control and Prevention (CDC); National Institutes of Health; HIV Medicine Association of the Infectious Diseases Society of America. MMWR2009;58:48–9
36.
Van der HorstCM, SaagMS, CloudGA, Treatment of cryptococcal meningitis associated with the acquired immune deficiency syndrome. N Engl J Med1997;337:15–21
37.
BrouwerA, RajanuwongA, ChierakulW, Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomized trial. Lancet2004;363:1764–7
38.
DromerF, Bernede-BauduinC, GuillemotD, LortholaryO. Major role for amphotericin B-flucytosine combination in severe cryptococcosis. PLoS ONE2008;3:e2870
39.
BicanicT, WoodR, MeintjesG, High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial. Clin Infect Dis2008;47:123–30
40.
BicanicT, MuzooraC, BrouwerA, Independent association between rate of clearance of infection and outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients. Clin Infect Dis2009;49:702–9
41.
NussbaumJC, JacksonA, NamarikaD, Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi. Clin Infect Dis2010;50:338–44
42.
ChenSC. Cryptococcosis in Australasia and the treatment of cryptococcal and other fungal infections with liposomal amphotericin B. J Antimicrob Chemother2002;49:57–61
43.
LeendersAC, ReissP, PortegeisP, Liposomal amphotericin B (Ambisome) compared with amphotericin B followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS1997;11:1463–71
44.
GraybillJR, SobelJ, SaagM. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups. Clin Infect Dis2000;30:47–5
45.
BicanicT, BrouwerAE, MeintjesG, Relationship of cerebrospinal fluid pressure, fungal burden and outcome in patients with cryptococcal meningitis undergoing serial lumbar punctures. AIDS. 2009;23:701–6
46.
FesslerRD, SobelJ, GuyotL, Management of elevated intracranial pressure in patients with cryptococcal meningitis. J Acquir Immune Defic Syndr Hum Retrovirol1998;17:137–42
47.
MacsweenKF, BicanicT, BrouwerAE, MarshH, MacallanDC, HarrisonTS. Lumbar drainage for control of raised cerebrospinal fluid pressure in cryptococcal meningitis: case report and review. J Infect2005;51:e221–4
48.
LongleyN, MuzooraC, TaseeraK, Dose response effect of high dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda. Clin Infect Dis2008;47:1556–61
49.
BicanicT, HarrisonT, NiepiekloA, DyakopuN, MeintjesG. Symptomatic relapse of HIV-associated cryptococcal meningitis after initial fluconazole monotherapy: the role of fluconazole resistance and immune reconstitution. Clin Infect Dis2006;43:1069–73
50.
PappasP, ChetchotisakdP, LarsenR, A phase II randomized trial of amphotericin B alone or combined with fluconazole in the treatment of HIV-associated cryptococcal meningitis. Clin Infect Dis2009;48:1775–83
51.
SaagMS, CloudGA, GraybillR. A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis1999;28:291–6
52.
VibhagoolA, SungkanuparphS, MootsikapunP, Discontinuation of secondary prophylaxis for cryptococcal meningitis in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy: a prospective, multicenter, randomized study. Clin Infect Dis2003;36:1329–31
53.
AbergJA, WatsonJ, SegalM, ChangLW. Clinical utility of monitoring serum cryptococcal antigen (sCRAG) titers in patients with AIDS-realted cryptococcal disease. HIV Clin Trials2000;1:1–6
54.
PowderlyWG, CloudGA, DismukesWE, SaagMS. Measurement of cryptococcal antigen in serum and cerebrospinal fluid: value in the management of AIDS-associated cryptococcal meningitis. Clin Infect Dis1994;18:789–92
ShelburneSA, DarcourtJ, WhiteCJr, The role of immune reconstitution inflammatory syndrome in AIDS related Cryptococcal neoformans disease in the era of highly active antiretroviral therapy. Clin Infect Dis2005;40:1049–52
57.
JarvisJN, LawnSD, VogtM, BanganiN, WoodR, HarrisonTS. Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clin Infect Dis2009;48:856–62
